Nanjing Pharmaceutical Company (600713.SH) released its semi-annual performance results, with a net profit attributable to shareholders of 291 million yuan, a year-on-year decrease of 6.44%.

- Wisdom Financial APP News, Nanjing Pharmaceutical (600713.SH) disclosed its semi-annual report for 2025, reporting that the company achieved a revenue of 27.967 billion yuan during the reporting period, an increase of 2.70% year-on-year; net profit attributable to shareholders was 291 million yuan, a decrease of 6.44% year-on-year; non-GAAP net profit was 262 million yuan, a decrease of 14.08% year-on-year; basic earnings per share were 0.222 yuan. The company plans to distribute a cash dividend of 1.70 yuan (tax included) for every 10 shares to all shareholders.